Feedback / Questions
BRG01 - Biosyngen
https://en.prnasia.com/releases/apac/biosyngen-received-china-nmpa-ind-approval-for-its-t-cell-redirection-therapy-targeting-ebv-positive-lymphoma-399596.shtml
Apr 11, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next